This study aimed to address whether bloodstream infections are a risk factor for the development of severe lupus flares, as well as clinical, immunological and microbiological features of patients with bloodstream infections that develop severe lupus flares.
Methods
We performed a retrospective cohort study comparing 87 systemic lupus erythematosus (SLE) patients with bloodstream infections and 87 hospitalized SLE patients without bloodstream infections as a comparison group. All patients were followed up for at least 3 months or until one of the primary outcomes was developed (severe SLE flare according to SELENA/SLEDAI score or death). Microbiological features of all bloodstream infections were recorded. The disease status at the end of follow up was registered.
Results
A total of 23 patients (13.2%) developed a severe flare during follow up; among them, 20 (87%) had an associated episode of bloodstream infection (p < 0.001). The most frequent flares were renal (43.4%) and severe thrombocytopenia (26%). After multivariate analysis, baseline-independent factors associated with severe SLE flare were bloodstream infection [hazard ratio (HR) 7.3, 95% confidence interval (CI) 2.13–24.95; p = 0.002]. Among patients with bloodstream infections, low C4 levels (HR 2.43, 95% CI 1.04–5.69: p = 0.04) and Streptococcus pneumoniae were associated with severe SLE flare (HR 3.41, 95% CI 1.68–6.91; p = 0.012).
Conclusions
SLE patients with bloodstream infections, especially due to S. pneumoniae, and low C4 levels, are at higher risk for development of severe SLE flares.
Al-RayesHAl-SwailemRArfinMet al.Systemic lupus erythematosus and infections: a retrospective study in Saudis. Lupus2007; 16: 755–763.
2.
DanzaARuiz-IrastorzaG. Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. Lupus2013; 22: 1286–1294.
3.
CuchacovichRGedaliaA. Pathophysiology and clinical spectrum of infections in systemic lupus erythematosus. Rheum Dis Clin North Am2009; 35: 75–93.
4.
ChenMJTsengHMHuangYLet al.Long-term outcome and short-term survival of patients with systemic lupus erythematosus after bacteraemia episodes: 6-yr follow-up. Rheumatology (Oxford)2008; 47: 1352–1357.
5.
DoriaACanovaMTononMet al.Infections as triggers and complications of systemic lupus erythematosus. Autoimmun Rev2008; 8: 24–28.
6.
SundarKJacquesSGottliebPet al.Expression of the Epstein-Barr virus nuclear antigen-1 (EBNA-1) in the mouse can elicit the production of anti-dsDNA and anti-Sm antibodies. J Autoimmun2004; 23: 127–140.
7.
AslanidisSPyrpasopoulouAKontotasiosKet al.Parvovirus B19 infection and systemic lupus erythematosus: Activation of an aberrant pathway?Eur J Intern Med2008; 19: 314–318.
8.
SinghHRaySKaurMet al.Exacerbation of latent lupus: is the culprit acid-fast bacilli or antitubercular therapy?Clin Rheumatol2013; 32: 1233–1236.
9.
Agmon-LevinNBlankMPazZet al.Molecular mimicry in systemic lupus erythematosus. Lupus2009; 18: 1181–1185.
10.
FourneauJMBachJMvan EndertPMet al.The elusive case for a role of mimicry in autoimmune diseases. Mol Immunol2004; 40: 1095–1102.
11.
RamachandranG. Gram-positive and gram-negative bacterial toxins in sepsis: a brief review. Virulence2014; 5: 213–218.
12.
CusickMFLibbeyJEFujinamiRS. Molecular mimicry as a mechanism of autoimmune disease. Clin Rev Allergy Immunol2012; 42: 102–111.
13.
FraserJD. Clarifying the mechanism of superantigen toxicity. PLoS One2011; 9: 4–4.
14.
GoldbergBUrnovitzHBStrickerRB. Beyond danger: unmethylated CpG dinucleotides and the immunopathogenesis of disease. Immunol Lett2000; 73: 13–18.
RiganteDEspositoS. Infections and Systemic Lupus Erythematosus: Binding or Sparring Partners?Int J Mol Sci2015; 16: 17331–17343.
17.
FrancisLPerlA. Infection in systemic lupus erythematosus: friend or foe?Int J Clin Rheumtol2010; 5: 59–74.
18.
Ruiz-IrastorzaGOlivaresNRuiz-ArruzaIet al.Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther2009; 11: 8–8.
19.
BoschXGuilabertAPallaresLet al.Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. Lupus2006; 15: 584–589.
20.
Merayo-ChalicoJGómez-MartínDPineirua-MenendezAet al.Lymphopenia as risk factor for development of severe infections in patients with systemic lupus erythematosus: a case-control study. QJM2013; 106: 451–457.
21.
Barrera-VargasAGómez-MartínDMerayo-ChalicoJet al.Risk Factors for Drug-resistant Bloodstream Infections in Patients with Systemic Lupus Erythematosus. J Rheumatol2014; 41: 7–7.
22.
TanEMCohenASFriesJFet al.The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271–1277.
23.
BombardierCGladmanDDUrowitzMBet al.Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum1992; 35: 630–640.
24.
BuyonJPPetriMKimMYet al.The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med2005; 142: 953–962.
25.
Rua-FigueroaILopez-LongoJGalindo-IzquierdoMet al.Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. Semin Arthritis Rheum2017. pii: S0049-0172(17)30075-6. doi: 10.1016/j.semarthrit.2017.01.010.
26.
JeongSJChoiHLeeHSet al.Incidence and risk factors of infection in a single cohort of 110 adults with systemic lupus erythematosus. Scand J Infect Dis2009; 41: 268–274.
27.
PetriMSinghSTesfasyoneHet al.Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study. J Rheumatol2009; 36: 2476–2480.
28.
PetriMAVan VollenhovenRFBuyonJet al.Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum2013; 65: 2143–2153.
29.
BirminghamDJIrshaidFNagarajaHNet al.The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus2010; 19: 1272–1280.
30.
GullstrandBMartenssonUSturfeltGet al.Complement classical pathway components are all important in clearance of apoptotic and secondary necrotic cells. Clin Exp Immunol2009; 156: 303–311.
31.
ChatterjeePAgyemangAFAlimzhanovMBet al.Complement C4 maintains peripheral B-cell tolerance in a myeloid cell dependent manner. Eur J Immunol2013; 43: 2441–2445.
32.
YammaniRDLeyvaMAJenningsRNet al.C4 Deficiency is a predisposing factor for Streptococcus pneumoniae-induced autoantibody production. J Immunol2014; 193: 5434–5443.
33.
BoeleLCBajramovicJJDe VriesAMet al.Activation of Toll-like receptors and dendritic cells by a broad range of bacterial molecules. Cell Immunol2009; 255: 17–25.
34.
DoriaASarzi-PuttiniPShoenfeldY. Infections, rheumatism and autoimmunity: the conflicting relationship between humans and their environment. Autoimmun Rev2008; 8: 1–4.
35.
SfrisoPGhirardelloABotsiosCet al.Infections and autoimmunity: the multifaceted relationship. J Leukoc Biol2010; 87: 385–395.
36.
Bekeredjian-DingIGreilJAmmannSet al.Plasmacytoid dendritic cells: neglected regulators of the immune response to Staphylococcus aureus. Front Immunol2014; 5: 238–238.
37.
ElkonKBStoneVV. Type I interferon and systemic lupus erythematosus. J Interferon Cytokine Res2011; 31: 803–812.
38.
GottenbergJEChiocchiaG. Dendritic cells and interferon-mediated autoimmunity. Biochimie2007; 89: 856–871.
39.
KwokSKLeeJYParkSHet al.Dysfunctional interferon-alpha production by peripheral plasmacytoid dendritic cells upon Toll-like receptor-9 stimulation in patients with systemic lupus erythematosus. Arthritis Res Ther2008; 10: R29–R29.
